n,n'-diisopropylurea is a symmetrical urea derivative with two isopropyl groups attached to the nitrogen atoms. It is a colorless crystalline solid at room temperature, soluble in various organic solvents. It is often used as a reagent in organic synthesis, particularly in the formation of amides and carbamates. The synthesis of n,n'-diisopropylurea typically involves the reaction of isopropylamine with phosgene or a phosgene equivalent. n,n'-diisopropylurea has also been studied for its potential applications in various fields, including pharmaceutical chemistry, materials science, and agriculture. Its unique structural features and properties make it a valuable compound for research and development.'
1,3-diisopropylurea: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 20084 |
| CHEMBL ID | 3186988 |
| SCHEMBL ID | 745482 |
| SCHEMBL ID | 20944295 |
| MeSH ID | M0231798 |
| Synonym |
|---|
| HMS1788L04 |
| 1,3-diisopropyl-urea |
| diptocarpamidine |
| urea,3-diisopropyl- |
| urea,n'-bis(1-methylethyl)- |
| nsc112719 |
| n,n'-diisopropylurea |
| nsc-112719 |
| 4128-37-4 |
| 1,3-diisopropylurea |
| AKOS000266567 |
| 1,3-di(propan-2-yl)urea |
| FT-0667207 |
| 1,3-bis(propan-2-yl)urea |
| EN300-52576 |
| dtxcid4024486 |
| tox21_301975 |
| dtxsid6044486 , |
| cas-4128-37-4 |
| 1,3-dipropan-2-ylurea |
| NCGC00255709-01 |
| unii-kt3mu4y10z |
| urea, n,n'-bis(1-methylethyl)- |
| urea, 1,3-diisopropyl- |
| einecs 223-940-5 |
| nsc 112719 |
| n,n'-bis(isopropyl)urea |
| kt3mu4y10z , |
| SCHEMBL745482 |
| (ch3)2-ch-nh-c(o)-nh-ch-(ch3)2 |
| diisopropyl urea |
| n,n'-di-isopropylurea |
| CHEMBL3186988 |
| mfcd00276304 |
| GEO-03835 |
| D93441 |
| SCHEMBL20944295 |
| Q27282426 |
| SY083966 |
| AS-75893 |
| CS-0153995 |
| Z94792417 |
| diquafosol impurity-diu |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 38.5708 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 46.9438 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||